Loss of the nuclear hormone receptor hepatocyte nuclear factor 4␣ (HNF4␣) in hepatocytes results in a complex pleiotropic phenotype that includes a block in hepatocyte differentiation and a severe disruption to liver function. Recent analyses have shown that hepatic gene expression is severely affected by the absence of HNF4␣, with expression of 567 genes reduced by >2.5-fold (P < 0.05) in Hnf4␣ ؊/؊ fetal livers. Although many of these genes are direct targets, HNF4␣ has also been shown to regulate expression of other liver transcription factors, and this raises the possibility that the dependence on HNF4␣ for normal expression of some genes may be indirect. We postulated that the identification of transcription factors whose expression is regulated by HNF4␣ might reveal roles for HNF4␣ in controlling hepatic functions that were not previously appreciated. Here we identify cyclic adenosine monophosphate responsive element binding protein H (CrebH) as a transcription factor whose messenger RNA can be identified in both the embryonic mouse liver and adult mouse liver and whose expression is dependent on HNF4␣. Analyses of genomic DNA revealed an HNF4␣ binding site upstream of the CrebH coding sequence that was occupied by HNF4␣ in fetal livers and facilitated transcriptional activation of a reporter gene in transient transfection analyses. Although CrebH is highly expressed during hepatogenesis, CrebH ؊/؊ mice were viable and healthy and displayed no overt defects in liver formation. However, upon treatment with tunicamycin, which induces an endoplasmic reticulum (ER)-stress response, CrebH ؊/؊ mice displayed reduced expression of acute phase response proteins. Conclusion: These data implicate HNF4␣ in having a role in controlling the acute phase response of the liver induced by ER stress by regulating expression of CrebH. (HEPATOLOGY 2008;48: 1242-1250 
H epatocyte gene expression is controlled by a complex network of transcription factors that is established during hepatogenesis. 1, 2 Recent studies have shown that the nuclear hormone receptor hepatocyte nuclear factor 4␣ (HNF4␣), as part of this network, is essential for initiating and maintaining hepatocyte differentiation and liver function. [3] [4] [5] [6] Loss of HNF4␣ in the fetal hepatoblasts results in reduced expression of over 500 genes encoding factors that contribute to all aspects of hepatic function. 6 HNF4␣ has also been shown to regulate expression of other transcription factors, including HNF1␣ 7, 8 and peroxisome proliferator-activated receptor ␣, 9 and this suggests that regulation of hepatocyte gene expression by HNF4␣ may in some cases be indirect. We therefore sought to uncover novel transcription factors that were expressed during hepatic development that could potentially be regulated by HNF4␣. We proposed that identification of such factors would implicate HNF4␣ in regulating aspects of liver function that heretofore were not recognized. In the current study, we report the identification of a cyclic adenosine monophosphate responsive element binding protein H (CrebH) (encoded by the gene Creb3l3), as a new target of HNF4␣ regulation that is expressed in differentiating hepatocytes throughout liver development and is essential for the expression of acute phase response proteins induced by endoplasmic reticulum (ER) stress.
Materials and Methods
Oligonucleotide Array Analysis. RNA was isolated from tissues with the RNeasy kit (Qiagen), and complementary RNA probes were prepared according to the directions described in the Affymetrix expression analysis technical manual.
RT-PCR. RT-PCR 3 and quantitative real-time RT-PCR 20 were performed as described previously. Primer sequences are available upon request.
In Situ Hybridization and Immunohistochemistry. In situ hybridization was performed as described elsewhere. 23 A probe used to detect CrebH was generated by in vitro transcription of a fragment from CrebH complementary DNA, which was generated by PCR using primers atcgaattcccatcagccctttcaactcc and atcggatccaggccagcctggtctacaag and subsequently cloned into the EcoR1/BamH1 sites of pBSII-KS. Immunohistochemistry was performed with previously described procedures 5 with antibodies that detect HNF4␣ (Santa Cruz sc-6556;1:500).
Chromatin Immunoprecipitation and EMSA. Immunoprecipitation of chromatin was performed with the Upstate ChIP assay kit (Upstate #17-295) as described previously, 6 and EMSA was performed as described elsewhere. 17 Analysis of Luciferase Expression. DNA was introduced into 293T cells with Lipofectamine Plus reagent (Invitrogen). Cell extracts were collected 48 hours after transfection and processed with a luciferase assay dual reporter system (Promega). Each experiment was performed in triplicate, the entire experiment was repeated on five separate occasions, and data were combined. Statistical significance was determined with the Student t test, with P Յ 0.05 considered significant. 997Gum ] mice has been described previously. 5, 16, 17, [24] [25] [26] Noon on the day of the appearance of a vaginal plug was considered to be 0.5 days post coitum, and the genotype of all embryos was determined by PCR analysis of genomic DNA. Pregnant mare serum gonadotropin, used in superovulation, was obtained from A.F. Parlow at the National Hormone and Peptide Program.
Results
CrebH Messenger RNA (mRNA) Is Highly Enriched in the Fetal Liver. Using Affymetrix oligonucleotide array analyses, we attempted to identify novel transcription factors whose expression was enriched in fetal livers. RNA was isolated from pools of livers, hearts, and heads that were dissected from E10.5 mouse embryos and used to generate probes that were hybridized to Affymetrix oligonucleotide GeneChip Murine Genome U74v2 A and B arrays. A comparison of liver, heart, and head arrays revealed 1208 genes whose expression was predicted to be increased Ͼ3.0-fold in the fetal liver samples compared to the heart and head samples. Of these genes, 78 encoded potential fetal liver-enriched transcription factors. 10 This list included Hnf4␣, CCAAT/enhancer binding protein alpha, Forkhead box A1 (Foxa1), and Foxa3 (see Supplementary Table 1) , all which have previously been shown to be expressed in hepatoblasts during embryonic development; however, other hepatoblast transcription factors, including HNF1␣, HNF1␤, and HNF6, were not identified, which suggested that the screen was not saturated.
Of the mRNAs identified, we chose to focus our analyses on CrebH because it was highly enriched in the fetal liver and was a member of the ATF/CREB family, other members of which are known to have important roles in controlling liver gene expression, and analyses of the human homolog of CrebH (CREBH) had been described as being exclusively expressed in the adult liver and undetectable in other tissues. 11 Using reverse-transcription polymerase chain reaction (RT-PCR), we first confirmed that CrebH mRNA was differentially expressed in the liver compared to the heart and head. Figure 1A shows that, like Albumin 1 (Alb1) mRNA, CrebH mRNA was enriched in three independent E10.5 liver samples compared to heart and head samples. Real-time quantitative RT-PCR (not shown) demonstrated that CrebH mRNA levels were 45 times greater in the liver compared to the heart. Hepatic Expression of CrebH Initiates During Liver Bud Formation and Continues Throughout Hepatogenesis. As a first step toward determining whether CrebH had the potential to act downstream of HNF4␣ during liver development and function, we com- pared expression of CrebH to that of Hnf4␣ during hepatic development. Livers were isolated from embryos at E10.5 through E18.5 and from adults, and mRNAs encoding CrebH and HNF4␣ were measured by RT-PCR. Figure 1B shows that CrebH is expressed in the liver at low levels early in development, begins to increase around E14.5, and continues increasing until maximal expression is reached in the adult liver. This dynamic pattern of expression is very similar to that of Hnf4␣, which was also seen to increase over this developmental time course. In situ hybridization analyses were next performed to assess expression of CrebH mRNA during the onset of hepatic development. Figure 1C ,F shows that during specification of the hepatic lineage from the ventral endoderm at E8.0 (6-8 somites), CrebH mRNA is restricted to the extraembryonic visceral endoderm, and it was not detected in the definitive endoderm, as has previously been described for Hnf4␣. 12, 13 Approximately a day later in development at E9.5, like Hnf4␣, 12, 13 CrebH mRNA was detected in the definitive endoderm forming the primary liver bud (Fig. 2D,G) , and expression continued in the hepatoblasts as they delaminated from the bud and invaded the surrounding septum transversum at E10.5 ( Fig.  1E,H) .
CrebH Is Expressed in the Epithelial Cells of the Adult Liver, Pyloric Stomach, and Small Intestine. The expression profile of CrebH mRNA in adult mouse tissues was next compared to that of Hnf4␣. RT-PCR analysis was performed with complementary DNA derived from a spectrum of adult mouse tissues ( Fig. 2A) . Hnf4␣ mRNA was identified in a variety of adult epithelial tissues, including the liver, kidney, and gastrointestinal tract, as described previously. [13] [14] [15] Like Hnf4␣, CrebH mRNA was identified in the liver, pyloric stomach, duodenum, and ileum; however, in contrast to Hnf4␣, CrebH mRNA was not identified in the kidney or colon. In sum, all tissues that expressed CrebH also expressed Hnf4␣ mRNA, although not all Hnf4␣-positive tissues expressed CrebH. The ability of the HNF4␣ protein to bind the putative HNF4␣-binding site was confirmed by EMSA. Radiolabeled oligonucleotides representing binding sites were incubated with liver nuclear extracts in the presence of anti-HNF4␣ antibody, and this resulted in a retarded migration of HNF4␣-bound complexes (arrows) or anti-Pes1 antibody (negative control). Alternatively, EMSAs were performed with nuclear extracts from COS-7 cells or COS-7 cells expressing HNF4␣. A previously described HNF4␣ binding site in the Apoc3 promoter served as a positive control, and a Foxa (Hnf3) binding site within the Ttr promoter served as a negative control. (C) 293T cells were transfected with plasmids in which expression of luciferase was driven by the HIV basal promoter (pZLHIVS) or, in addition, a 207-bp fragment from the CrebH gene that contained the HNF4␣ binding site (pCrebH-Luc1) in the presence or absence of exogenously expressed HNF4␣. Luciferase levels from five independent experiments are presented as fold differences with respect to cells transfected with pZLHIVS alone. Significance was determined by the Student t test (P Ͻ 0.05). (D) ChIP analyses were performed on chromatin extracted from two independent E18.5 livers (L1 and L2) or brains (B1 and B2), which acted as negative control tissue that did not express HNF4␣. Chromatin was precipitated with anti-HNF4␣ or anti-Pes1 (negative control), and specific primers were used to amplify input chromatin or chromatin precipitated from the Pol2 promoter (negative control), Apoc3 promoter (positive control), or CrebH.
We next performed in situ hybridization to identify the specific cell types that expressed CrebH mRNA. Tissues lacking CrebH mRNA, such as the kidney (based on RT-PCR analysis), showed no hybridization above background and therefore acted as convenient negative controls (data not shown). CrebH mRNA was detected in the hepatocytes of the adult liver (Fig. 2B,E) and in the epithelium of the villi, but not the crypts, of the small intestine (Fig. 2C,F) . CrebH transcripts were also identified in the surface epithelial cells of the pyloric stomach (Fig. 2D,G) but not in the glands.
HNF4␣ Regulates Transcription Through an HNF4␣-Binding Site Within the Putative Transcriptional Regulatory Region of the CrebH Gene. The aforementioned expression studies demonstrated that following the specification of the hepatic cell lineage, CrebH is continuously expressed in the hepatic cells throughout liver development in a manner indistinguishable from HNF4␣, raising the possibility that CrebH is a direct transcriptional target of HNF4␣. To identify potential DNA sequences that could facilitate HNF4␣-mediated expression of CrebH, we therefore examined 27.5 kb of the CrebH genomic DNA sequence, including sequences extending 10 kb upstream of exon 1, for the presence of any of 215 known HNF4␣ binding sites, using an HNF4␣ motif finder generated by Sladek and colleagues (http://www.sladeklab.ucr.edu/links.html). This analysis identified a single potential HNF4␣ binding site (H4.77) lying 3.7 kb upstream of CrebH exon 1 (Fig. 3A) . The ability of HNF4␣ to bind the aforementioned sequence was confirmed with electrophoretic mobility shift analyses (EMSAs) on nuclear extracts from adult liver. Figure  3B shows that HNF4␣ protein could be detected in a complex with a well-characterized binding site (H4.21; see http://bioinfo.ucr.edu/ϳebolotin/h4supp.html) from the Apolipoprotein c3 (Apoc3) gene, 14 which could be converted to a slower migrating complex by inclusion of anti-HNF4␣ antibody. A complex with a similar migration pattern was identified when the same extracts were incubated with the H4.77 HNF4␣-binding site from the CrebH gene, but not when extracts were incubated with a FoxA transcription factor binding site from the Transthyretin (Ttr) gene, which acted as a control for binding specificity. Similar results were obtained when extracts from COS-7 cells expressing exogenous HNF4␣ were used (Fig. 3B) . Other protein-DNA complexes were also detected in the extracts and likely reflect the binding of additional proteins known to interact with HNF4␣ binding sites, such as retinoid A receptor, retinoid X receptor, and chicken ovalbumin upstream promoter transcription factor.
The ability of exogenous HNF4␣ to activate transcription via the HNF4␣ binding site within the putative CrebH promoter region was studied by transient transfection analyses in 293T cells, which do not express endogenous HNF4␣. Figure 3C shows that luciferase levels measured in 293T cells transfected with a reporter plasmid containing only the human immunodeficiency virus (HIV) basal promoter to regulate transcription of the luciferase reporter gene (pHIV-Luc) were not affected by the additional introduction of exogenously expressed HNF4␣. Similar results were obtained when 293T cells were transfected with the same reporter plasmid containing an additional 123-bp element from CrebH that included the HNF4␣-binding site (pCrebH-Luc). However, the introduction of exogenously expressed HNF4␣ to pCrebH-Luc-transfected 293T cells now resulted in an approximately 2.5-fold induction (Student t test, P Յ 0.05) of luciferase activity in comparison with controls, and this demonstrated that HNF4␣ can activate transcription through this element of the CrebH gene.
Using chromatin immunoprecipitation (ChIP) analyses, we next addressed whether HNF4␣ could occupy the identified binding site within the endogenous CrebH gene in fetal livers. Figure 3D shows that, in contrast to se- quences from the Pol2 gene that do not contain HNF4␣ binding sites, a known HNF4␣ binding site within the Apoc3 promoter (H4.21) as well as the HNF4␣ binding site within the CrebH gene could be precipitated from chromatin isolated from fetal livers with an antibody that specifically recognizes HNF4␣. Importantly, the levels of products identified when precipitations were performed on brain extracts, which lack HNF4␣, or when liver extracts were precipitated with an unrelated antibody (antiPes) were low to undetectable. Cumulatively, these data demonstrate that the CrebH gene contains an HNF4␣ recognition element that is occupied by HNF4␣ in fetal livers.
HNF4␣ Is Essential for Expression of CrebH in the Fetal Liver but Dispensable for Expression in the Small Intestine. To definitively determine whether
CrebH expression is dependent on HNF4␣, we generated E18.5 embryos in which HNF4␣ was specifically deleted in differentiating hepatocytes (Hnf4␣ loxP/loxP Alfp.cre), 5, 16 colonic epithelial cells (Hnf4␣ loxP/loxP FoxA3.cre), 17 or small intestine epithelial cells (Hnf4␣ loxP/loxP Villin.cre), and we measured CrebH levels by RT-PCR. Figure 4 shows that although CrebH expression was detected in two different control livers, it was not identified in HNF4␣-null livers under identical conditions. As expected, CrebH was also undetectable in colons regardless of the presence or absence of HNF4␣. Somewhat surprisingly, and in contrast to the liver, CrebH mRNA was detected in both control and HNF4␣-null small intestines. We therefore conclude that HNF4␣ is dispensable for CrebH expression in the gastrointestinal tract but is essential for CrebH expression in the liver.
CrebH Is Dispensable for Hepatogenesis and Hepatocyte Differentiation. The finding that fetal liver expression of CrebH is dependent on the presence of HNF4␣ raised the question of whether the absence of CrebH could account for any aspect of the phenotype associated with Hnf4␣ Ϫ/Ϫ fetal livers. To test this, we generated two strains of mice, one of which harbored a null allele of CrebH (CrebH Ϫ/Ϫ ) and the other of which harbored a CrebH allele that could be conditionally disrupted by expression of Cre recombinase (CrebH loxP/loxP ). Details of the targeting strategy are shown in Fig. 5A . Briefly, embryonic stem cells (CrebH ϩ/loxPNeo ) were generated that contained a single loxP site between exons 11 and 12 of CrebH and a cassette, which was flanked by frt sites, containing a loxP site lying 5Ј to the neomycin phosphotranferase gene between exons 3 and 4 of CrebH. Correct targeting of the CrebH locus was confirmed by Southern blot analyses of genomic DNA (Fig. 5B,C) , and the altered CrebH allele was successfully transmitted through the germ line to generate CrebH ϩ/loxPNeo mice. We finally generated mice harboring a null allele of CrebH (CrebH ϩ/Ϫ ) by mating CrebH ϩ/loxPNeo mice with an EIIa-Cre transgenic mouse [B6.FVB-Tg(EIIa-cre)C5379Lmgd/J], and this resulted in Cre-mediated recombination between loxP sites in the germ line 18 (Fig. 5A,D) . We also produced mice containing a conditionally null CrebH allele (CrebH ϩ/ loxP) by mating CrebH ϩ/loxPNeo mice with mice expressing Flp recombinase from the human ␤-actin gene promoter [B6; SJL-Tg(ACTFLPe)9205Dym/J] 19 (Fig. 5A,E) .
If CrebH were essential for a central aspect of hepatogenesis, we predicted that CrebH Ϫ/Ϫ embryos would die during late gestation stages. However, crosses of CrebH ϩ/Ϫ mice yielded CrebH Ϫ/Ϫ offspring at the expected Mendelian ratio as determined with polymerase chain reaction (PCR) analyses of genomic DNA isolated from 162 weanlings. RT-PCR analyses identified CrebH mRNA in control livers but not in CrebH Ϫ/Ϫ livers (Fig.  5F ), and this is consistent with a loss of CrebH activity in the mutant mice. CrebH Ϫ/Ϫ mice were found to be longlived, fecund, and apparently healthy. Examination of E18.5 embryos revealed no obvious difference between control and mutant embryos (Fig. 6A) , and the overall anatomy of the liver and gastrointestinal tract of CrebH Ϫ/Ϫ embryos appeared to be normal. Hematoxylineosin (H&E) histological staining and HNF4␣ immunohistochemistry performed on sections through E18.5 CrebH Ϫ/Ϫ livers found them to be indistinguishable from sections through control livers (Fig. 6B) . Finally, oligonucleotide array analyses revealed that mRNA levels were comparable between control and mutant embryos (not shown). Cumulatively, these data demonstrate that CrebH is dispensable for hepatogenesis and hepatocyte differentiation in the mouse.
Loss of CrebH Results in Reduced Expression of Acute Phase Response Proteins Induced by Tunicamycin.
CrebH is a member of the CREB/ATF family of bZip transcription factors that contains a transmembrane domain that directs its localization to the ER. 11, 20 Recent work has shown that ER stress results in proteolytic cleavage of CrebH, allowing the N-terminus to translocate to the nucleus, where it can activate transcription of target genes including those involved in the acute phase response. 20, 21 We therefore examined whether the expression of acute phase genes in response to treatment with tunicamycin, which induces ER stress by blocking glycosylation and protein folding, was affected in CrebH Ϫ/Ϫ mice. Figure 7 shows that the expression of mRNAs encoding the acute phase response proteins C-reactive protein (CRP), serum amyloid P-component (SAP), and serum amyloid A3 (SAA3) was robustly induced in CrebH ϩ/ϩ mice in response to treatment with tunicamycin as expected. However, in contrast to control animals, when CrebH Ϫ/Ϫ mice were treated with tunicamycin, the expression of each of these acute phase mRNAs was severely reduced. Similar results were obtained for both liver and serum SAP protein levels (see Supplementary  Fig. 8 ). These results confirm that CrebH is an important component of the systemic inflammatory response to ER stress. Moreover, they imply an indirect role for HNF4␣ in this response by mediating CrebH expression.
Discussion
In the current analyses, we have identified CrebH as a direct target of HNF4␣. Although our data support the view that CrebH expression is strictly dependent on HNF4␣ in the liver, we have also found that CrebH continues to be robustly expressed in HNF4␣-null small intestines. Moreover, although HNF4␣ is dispensable for intestinal CrebH expression, ChIP analyses have revealed that, like the liver, HNF4␣ occupies its binding site within the CrebH promoter in intestinal tissue (data not shown). These data suggest that the regulation of CrebH by HNF4␣ is tissue-dependent and importantly that occupancy of a promoter by HNF4␣ in vivo does not necessarily correlate with transcriptional regulation. 1 It is intriguing that CrebH expression is independent of HNF4␣ in the small intestine yet is strictly dependent on HNF4␣ in the liver. One possible explanation could be that an intestinal regulatory element exists within the CrebH promoter that is controlled specifically by intestinal transcription factors, thereby obviating any requirement for HNF4␣. Alternatively, HNF4␥, which in contrast to the liver is robustly expressed in the gut, could potentially compensate for loss of HNF4␣ in Hnf4␣ loxP/loxP Villin.cre mice. Efforts to address possible redundancy between these two HNF4 family members through the generation of Hnf4g Ϫ/Ϫ animals are currently underway.
To examine the role of CrebH in liver function, we generated CrebH Ϫ/Ϫ mice that were viable and healthy. Although at the onset of the project very little was known about this member of the CREB/ATF family of transcription factors, a number of reports have recently emerged that raise a potential role for this factor in controlling hepatic function. 11, [20] [21] [22] Most relevant is the finding by Zhang et al. 20 that proinflammatory cytokines or ER stress could activate CrebH through proteolytic cleavage and that depletion of CrebH with short hairpin RNA inhibited expression of acute phase proteins. 20 In addition, CrebH was shown to transactivate expression of a luciferase reporter gene through the CRP and SAP promoters, and this suggested that CrebH directly regulates expression of these acute phase genes. We therefore examined the expression of mRNAs encoding acute phase response proteins in CrebH Ϫ/Ϫ mice following a treatment with tunicamycin that induced ER stress. We found that expression of CRP, SAP, and SAA3 mRNAs following treatment was severely diminished in CrebH Ϫ/Ϫ animals compared to controls. Although our data confirm an important role for CrebH in the liver, the contribution of CrebH to gut function, particularly in response to ERinduced stress, remains to be determined. However, with the availability of CrebH loxP/loxP mice, it should be possible to address this issue in future studies.
In conclusion, these results confirm that CrebH has an important role in a pathway that controls expression of acute phase proteins in response to ER stress. Moreover, because hepatic expression of CrebH is dependent on HNF4␣, these results demonstrate that HNF4␣ makes an indirect yet crucial contribution toward the induction of a systemic inflammatory response by ER stress. Fig. 7 . The response to tunicamycin-induced ER stress is reduced by the loss of CrebH. CrebH ϩ/ϩ (gray bars) and CrebH Ϫ/Ϫ (white bars) mice were given tunicamycin (2 g/g of body weight) by intraperitoneal injection. Livers were isolated at 24 hours and processed for quantitative RT-PCR of mRNAs encoding the acute phase proteins (A) CRP, (B) SAA3, and (C) SAP.
